Drug Search Results
More Filters [+]

GS-9901

Alternative Names: gs-9901, gs9901, gs 9901
Latest Update: 2015-10-19
Latest Update Note: Clinical Trial Update

Product Description

Gilead Sciences was developing gs-9901, an oral PI3K Inhibitor for adults with follicular lymphoma (FL), marginal zone lymphoma (MZL), chronic lymphocytic leukemia (CLL), or small lymphocytic lymphoma (SLL)

Mechanisms of Action: PI3K Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Gilead Sciences
Company Location: FOSTER CITY CA 94404
Company CEO: Daniel P. O’Day
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for GS-9901

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Chronic Lymphoid Leukemia|Follicular Lymphoma|Lymphocytic Chronic B-Cell Leukemia|B-Cell Marginal Zone Lymphoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

GS-US-325-1348

P1

Terminated

Lymphocytic Chronic B-Cell Leukemia|Follicular Lymphoma|Chronic Lymphoid Leukemia|B-Cell Marginal Zone Lymphoma

2015-08-01

Recent News Events

Date

Type

Title